Prevalence of pretreatment HIV resistance to integrase inhibitors in West African and Southeast Asian countries

2024

Article référencé dans le Web of Science WOS:001193072500001

Aghokeng Fobang Avelin, Ngo-Giang-Huong Nicole, Huynh T. H. K., Dagnra A. Y., Toni T. D., Maiga A., Dramane K., Eymard-Duvernay Sabrina, Chaix M. L., Calvez V., Descamps D.

Journal of Antimicrobial Chemotherapy, 2024, 79 (5), 1164-1168 ISSN 0305-7453

Objectives Integrase strand transfer inhibitors (INSTIs) have been recently recommended as the preferred first-line option for antiretroviral treatment initiators in low- and middle-income countries (LMICs) in response to the growing circulation of resistant HIV to non-nucleoside reverse transcriptase inhibitors (NNRTIs). In this study, we estimated the frequency of pretreatment drug resistance (PDR) to INSTIs in West Africa and Southeast Asia. Materials and methods Using samples collected from 2015 to 2016, and previously used to assessed PI, NRTI and NNRTI resistance, we generated HIV integrase sequences and identified relevant INSTI PDR mutations using the Stanford and ANRS algorithms.Results We generated 353 integrase sequences. INSTI PDR frequency was low, 1.1% (4/353) overall, ranging from 0% to 6.3% according to country. However, frequency of PDR to any drug class was very high, 17.9% (95% CI: 13.9%-22.3%), and mostly associated with a high level of NNRTI PDR, 9.7%, and a moderate level of NRTI PDR, 5.3%.Conclusions Our results support the recent introduction of INSTIs in LMICs to improve treatment outcome in these settings, but also stress the need for effective actions to prevent uncontrolled emergence of drug resistance to this drug class.

Santé : généralités [050] ; Entomologie médicale / Parasitologie / Virologie [052]

AFRIQUE DE L'OUEST ; ASIE DU SUD EST

Fonds IRD [F B010091603]

fdi:010091603